A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber
- Registration Number
- NCT01804400
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
This study will assess the safety and efficacy of QAW039 alone and in combination with Montelukast in patients with allergic rhinitis (hay fever) using an environmental exposure chamber.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 188
- Male or female aged 18-65 years inclusive, with a clinical history of intermittent allergic rhinitis with seasonal onset and offset of nasal allergy symptoms during each of the last two grass pollen allergy seasons.
- A positive skin prick test at Visit 1 to dactylis glomerata with a wheal diameter equal to or greater than 3 mm and a negative control with a wheal diameter of zero. A positive skin prick test within 12 months prior to Visit 1 is also acceptable.
- FEV1 measured by spirometry must be ≥80% of their predicted value at screening. If the patient does not achieve ≥80% of their predicted value this may be repeated prior to the EEC challenge at visit 2.
- TNSS score ≥6 on at least one assessment during the 2h EEC challenge at Screening.
- Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer; or longer if required by local regulations, and for any other limitation of participation in an investigational trial based on local regulations.
- Pregnant or nursing (lactating) women,
- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description QAW039 Once a day (q.d.) QAW039 - QAW039 Once a day (q.d.) Placebo - QAW039 Twice a day (b.i.d.) QAW039 - QAW039 Twice a day (b.i.d.) Placebo - Montelukast Placebo - Placebo Placebo - QAW039 + Montelukast QAW039 - QAW039 + Montelukast Placebo - QAW039 + Montelukast Montelukast - Montelukast Montelukast -
- Primary Outcome Measures
Name Time Method Change in Total Nasal Symptom Score from baseline at 14 days Baseline, Day 14 Total Nasal Symptom Score (TNSS) averaged over the last two hours (2-4h) of exposure following 14 days treatment with QAW039 and/or Montelukast or matched placebo
- Secondary Outcome Measures
Name Time Method Change in Total Ocular Symptom score from Baseline at 14 days Baseline, Day 14 Total Ocular Symptom Score (TOSS), defined as the sum of ocular symptoms of eye tearing, itching, watery eyes and redness, each of which is scored on a scale from 0 and 3
Change in Nasal Flow from baseline at 14 days Prior to, and every 60 min during allergen exposure period Measured using rhinomanometry Flow rates at 150 Pa will be obtained separately for the right and left nostrils (cm\^3/second). The sum of the flow rates of both nostrils will be calculated from the two measurements
Change in Nasal excretion weight from baseline at 14 days Baseline, Day 14 Total weight of tissues (before and after use)
Change in Forced Expiratory Volume in 1 Second (FEV1) from baseline at 14 days Baseline, Day 14 Change in FEV1 from Baseline
Change in FEV1/FVC at from baseline at 14 days Baseline, Day 14 Change in FEV1/FVC from Baseline
Plasma Concentration maximum (Cmax) Day 1-14 Determined at steady state in plasma
Plasma Concentration Minimum (Cmin) Day 1-14 Determined at steady state in plasma
Change in Forced Vital Capacity (FVC) from baseline at 14 days Baseline, Day 14 Change in FVC from Baseline
Plasma Concentration Average (Cav) Day 1-14 Determined at steady state in plasma
Time of Cmax (Tmax) Day 1-14 Determined at steady state in plasma
Area Under Curve (AUCtau) Day 1-14 Determined at steady state in plasma
Trial Locations
- Locations (1)
Novartis Investigative Site
🇩🇪Hannover, Germany